SCHEMBL79746

SCHEMBL79746

CCOC(=O)C(C)(C)C(C)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 2/20 0.47
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP4F2 P78329 3/20 0.41
CYP4A11 Q02928 3/20 0.41
ALDH1A1 P00352 3/20 0.40
PKM P14618 3/20 0.39
LMNA P02545 1/20 0.39
HSD17B10 Q99714 1/20 0.39
KDM4E B2RXH2 1/20 0.38
THRB P10828 1/20 0.37
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
GAA P10253 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
ABCB11 O95342 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5515278 0.84 MMP8 (0.48) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL13256822 0.83 MMP8 (0.44) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL28718222 0.80 MMP8 (0.46) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL8112891 0.80 MMP8 (0.46) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL27895587 0.80 TSHR (0.42) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL1370735 0.80 MMP8 (0.46) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL19690677 0.80 MMP8 (0.46) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL9584905 0.78 MMP8 (0.44) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL6596388 0.78 MMP8 (0.44) MMP8MEN1KMT2ACYP4F2CYP4A11
SCHEMBL27318502 0.78 MMP8 (0.44) MMP8MEN1KMT2ACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117304863-A LED-UV (light-emitting diode-ultraviolet) curing type strippable protective adhesive as well as preparation method and application thereof 天津科技大学 2023-12-29 CN claimed
US-20240415847-A1 BETA-LACTAMASE INHIBITORS AND USES THEREOF ARIXA PHARMACEUTICALS, INC. (US) 2024-12-19 US disclosed
EP-3860999-B9 DERIVATIVES OF RELEBACTAM AND USES THEREOF ARIXA PHARMACEUTICALS INC (US) 2024-08-14 EP disclosed
EP-3860999-B1 DERIVATIVES OF RELEBACTAM AND USES THEREOF ARIXA PHARMACEUTICALS INC (US) 2024-06-05 EP disclosed
CN-117304863-A LED-UV (light-emitting diode-ultraviolet) curing type strippable protective adhesive as well as preparation method and application thereof 天津科技大学 2023-12-29 CN disclosed
EP-3625233-B9 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS ARIXA PHARMACEUTICALS INC (US) 2023-10-25 EP disclosed
EP-3625233-B1 3-(((((2S,5R)-2-CARBAMOYL-7-OXO-1,6-DIAZABICYCLO[3.2.1]OCTAN-6-YL)OXY)SULFONYL)OXY)-2,2-DIMETHYLPROPANOATE DERIVATIVES AND RELATED COMPOUNDS AS PERORALLY ADMINISTERED PROFRUGS OF BETA-LACTAMASE INHIBITORS FOR TREATING BACTERIAL INFECTIONS ARIXA PHARMACEUTICALS INC (US) 2023-07-12 EP disclosed
US-20230201218-A1 BETA-LACTAMASE INHIBITORS AND USES THEREOF ARIXA PHARMACEUTICALS, INC. (US) 2023-06-29 US disclosed
EP-3676247-B1 AZTREONAM DERIVATIVES AND USES THEREOF ARIXA PHARMACEUTICALS INC (US) 2023-03-08 EP disclosed
EP-3307413-B1 BRAIN DERIVED PPAR LIGANDS UNIV RUSH MEDICAL CENTER (US) 2022-12-28 EP disclosed
US-7566787-B2 Small molecule cyclin D1 ablative agents THE OHIO STATE UNIVERSITY (US) 2009-07-28 US disclosed
US-20080221122-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE BEYONDSPRING PHARMACEUTICALS, INC. 2008-09-11 US disclosed
US-20080221122-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE BEYONDSPRING PHARMACEUTICALS, INC. 2008-09-11 US disclosed
US-20080213510-A1 Liquid Crystal Aligning Agent and Liquid Crystal Alignment Layer Formed Using the Same CHEIL INDUSTRIES INC. (KR) 2008-09-04 US disclosed
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
US-20070078138-A1 Analogs of dehydrophenylahistins and their therapeutic use BEYONDSPRING PHARMACEUTICALS, INC. 2007-04-05 US disclosed
US-20070078138-A1 Analogs of dehydrophenylahistins and their therapeutic use BEYONDSPRING PHARMACEUTICALS, INC. 2007-04-05 US disclosed
EP-0320096-B1 PROCESS FOR ASYMMETRICALLY REDUCING CARBONYL COMPOUNDS AJINOMOTO CO., INC. (JP) 1991-08-21 EP disclosed
US-4943652-A Process for asymmetrically reducing carbonyl compounds AJINOMOTO CO., INC. (JP) 1990-07-24 US disclosed
EP-0320096-A1 Process for asymmetrically reducing carbonyl compounds AJINOMOTO CO., INC. (JP) 1989-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 MMP8 4673/4885MEN1 993/4885KMT2A 318/4885
US-20230201218-A1 BETA-LACTAMASE INHIBITORS AND USES THEREOF GAA, LCT, MGAM MMP8 99/4885MEN1 3937/4885KMT2A 3236/4885
US-20070078138-A1 Analogs of dehydrophenylahistins and their therapeutic use MKI67, HPGDS, HCCS MMP8 765/4885MEN1 2488/4885KMT2A 3656/4885
US-20080221122-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE HPGDS, DHPS, HCCS MMP8 874/4885MEN1 2127/4885KMT2A 3119/4885
US-20240415847-A1 BETA-LACTAMASE INHIBITORS AND USES THEREOF GAA, LCT, MGAM MMP8 99/4885MEN1 3937/4885KMT2A 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.